Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

196 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Liquid biopsy mutation panel for non-small cell lung cancer: analytical validation and clinical concordance.
Schwartzberg LS, Horinouchi H, Chan D, Chernilo S, Tsai ML, Isla D, Escriu C, Bennett JP, Clark-Langone K, Svedman C, Tomasini P; Oncotype SEQ® Study Investigators and Program Team. Schwartzberg LS, et al. Among authors: svedman c. NPJ Precis Oncol. 2020 Jun 24;4:15. doi: 10.1038/s41698-020-0118-x. eCollection 2020. NPJ Precis Oncol. 2020. PMID: 32596507 Free PMC article.
[No title available]
[No authors listed] [No authors listed] PMID: 33594186
A 16-gene assay to predict recurrence after surgery in localised renal cell carcinoma: development and validation studies.
Rini B, Goddard A, Knezevic D, Maddala T, Zhou M, Aydin H, Campbell S, Elson P, Koscielny S, Lopatin M, Svedman C, Martini JF, Williams JA, Verkarre V, Radulescu C, Neuzillet Y, Hemmerlé I, Timsit MO, Tsiatis AC, Bonham M, Lebret T, Mejean A, Escudier B. Rini B, et al. Among authors: svedman c. Lancet Oncol. 2015 Jun;16(6):676-85. doi: 10.1016/S1470-2045(15)70167-1. Epub 2015 May 12. Lancet Oncol. 2015. PMID: 25979595
Validation of the 16-Gene Recurrence Score in Patients with Locoregional, High-Risk Renal Cell Carcinoma from a Phase III Trial of Adjuvant Sunitinib.
Rini BI, Escudier B, Martini JF, Magheli A, Svedman C, Lopatin M, Knezevic D, Goddard AD, Febbo PG, Li R, Lin X, Valota O, Staehler M, Motzer RJ, Ravaud A. Rini BI, et al. Among authors: svedman c. Clin Cancer Res. 2018 Sep 15;24(18):4407-4415. doi: 10.1158/1078-0432.CCR-18-0323. Epub 2018 May 17. Clin Cancer Res. 2018. PMID: 29773662 Clinical Trial.
Clinical outcomes in patients with node-negative breast cancer treated based on the recurrence score results: evidence from a large prospectively designed registry.
Stemmer SM, Steiner M, Rizel S, Soussan-Gutman L, Ben-Baruch N, Bareket-Samish A, Geffen DB, Nisenbaum B, Isaacs K, Fried G, Rosengarten O, Uziely B, Svedman C, McCullough D, Maddala T, Klang SH, Zidan J, Ryvo L, Kaufman B, Evron E, Karminsky N, Goldberg H, Shak S, Liebermann N. Stemmer SM, et al. Among authors: svedman c. NPJ Breast Cancer. 2017 Sep 8;3:33. doi: 10.1038/s41523-017-0034-6. eCollection 2017. NPJ Breast Cancer. 2017. PMID: 28900633 Free PMC article.
The MAGIC survey in hormone receptor positive (HR+), HER2-negative (HER2-) breast cancer: When might multigene assays be of value?
Aapro M, De Laurentiis M, Rea D, Bargallo Rocha JE, Elizalde R, Landherr L, Linderholm B, Mamounas E, Markopoulos C, Neven P, Petrovsky A, Rouzier R, Smit V, Svedman C, Schneider D, Thomssen C, Martin M. Aapro M, et al. Among authors: svedman c. Breast. 2017 Jun;33:191-199. doi: 10.1016/j.breast.2017.01.012. Epub 2017 Apr 22. Breast. 2017. PMID: 28441617
In the era of genomics, should tumor size be reconsidered as a criterion for neoadjuvant chemotherapy?
Pivot X, Mansi L, Chaigneau L, Montcuquet P, Thiery-Vuillemin A, Bazan F, Dobi E, Sautiere JL, Rigenbach F, Algros MP, Butler S, Jamshidian F, Febbo P, Svedman C, Paget-Bailly S, Bonnetain F, Villanueva C. Pivot X, et al. Among authors: svedman c. Oncologist. 2015 Apr;20(4):344-50. doi: 10.1634/theoncologist.2014-0198. Epub 2015 Mar 20. Oncologist. 2015. PMID: 25795632 Free PMC article. Clinical Trial.
West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment.
Gluz O, Nitz UA, Christgen M, Kates RE, Shak S, Clemens M, Kraemer S, Aktas B, Kuemmel S, Reimer T, Kusche M, Heyl V, Lorenz-Salehi F, Just M, Hofmann D, Degenhardt T, Liedtke C, Svedman C, Wuerstlein R, Kreipe HH, Harbeck N. Gluz O, et al. Among authors: svedman c. J Clin Oncol. 2016 Jul 10;34(20):2341-9. doi: 10.1200/JCO.2015.63.5383. Epub 2016 Feb 29. J Clin Oncol. 2016. PMID: 26926676 Clinical Trial.
Genomic profile of breast cancer.
Plun-Favreau J, Svedman C, Valentine W, Rouzier R. Plun-Favreau J, et al. Among authors: svedman c. Expert Rev Pharmacoecon Outcomes Res. 2015 Jun;15(3):393-4. doi: 10.1586/14737167.2015.1025758. Epub 2015 Mar 23. Expert Rev Pharmacoecon Outcomes Res. 2015. PMID: 25797274 No abstract available.
196 results